Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 6/20 | 0.52 |
| ▸ | RARB | P10826 | 1/20 | 0.41 |
| ▸ | RARG | P13631 | 1/20 | 0.41 |
| ▸ | RXRA | P19793 | 1/20 | 0.41 |
| ▸ | RXRB | P28702 | 1/20 | 0.41 |
| ▸ | RXRG | P48443 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | UNG | P13051 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | LCK | P06239 | 1/20 | 0.35 |
| ▸ | FYN | P06241 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16888780 | 0.81 | CA2 (0.47) | DAORARBRARGRXRARXRB | |
| SCHEMBL2552759 | 0.79 | ERN1 (0.51) | RXRARXRBALDH1A1MEN1NPC1 | |
| SCHEMBL7885949 | 0.76 | ERN1 (0.41) | DAOALDH1A1FYNERN1HPGD | |
| SCHEMBL29100404 | 0.76 | ALDH1A1 (0.36) | DAOALDH1A1UNGTSHRL3MBTL1 | |
| SCHEMBL2940872 | 0.76 | ALDH1A1 (0.47) | ALDH1A1MEN1GAAKMT2ATSHR | |
| SCHEMBL2556885 | 0.75 | KMO (0.56) | RXRARXRBALDH1A1UNGGAA | |
| SCHEMBL15332306 | 0.75 | CA12 (0.47) | DAOALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL6891489 | 0.75 | DAO (0.48) | DAORARBRARGRXRARXRB | |
| SCHEMBL6891483 | 0.75 | DAO (0.48) | DAORARBRARGRXRARXRB | |
| SCHEMBL15331511 | 0.74 | HCAR1 (0.43) | DAOHCAR2ERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 161 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12459956-B2 | Heterobicyclic carboxamides and uses thereof | ALCON INC. (CH) | 2025-11-04 | — | — | US | disclosed |
| CN-119241504-A | Spiroindoline inhibitors of KIF18A | 沃拉斯查疗法公司 | 2025-01-03 | — | — | CN | disclosed |
| US-20240351984-A1 | INDOLINE COMPOUNDS FOR INHIBITING KIF18A | VOLASTRA THERAPEUTICS, INC. (US) | 2024-10-24 | — | — | US | disclosed |
| US-12084420-B2 | Indoline compounds for inhibiting KIF18A | VOLASTRA THERAPEUTICS, INC. (US) | 2024-09-10 | — | — | US | disclosed |
| EP-4392407-A1 | SPIRO INDOLINE INHIBITORS OF KIF18A | Volastra Therapeutics, Inc. (US) | 2024-07-03 | — | — | EP | disclosed |
| CN-118103352-A | Spiroindoline inhibitors of KIF18A | 沃拉斯查疗法公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-117377665-A | PARP7 inhibitor and application thereof | 北京华森英诺生物科技有限公司 | 2024-01-09 | — | — | CN | disclosed |
| US-20230147507-A1 | INDOLINE COMPOUNDS FOR INHIBITING KIF18A | VOLASTRA THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230147507-A1 | INDOLINE COMPOUNDS FOR INHIBITING KIF18A | VOLASTRA THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230147507-A1 | INDOLINE COMPOUNDS FOR INHIBITING KIF18A | VOLASTRA THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| WO-1997048672-A2 | SUBSTITUTED TETRAHYDRONAPHTHALENE AND DIHYDRONAPHTHALENE DERIVATIVES HAVING RETINOID AND/OR RETINOID ANTAGONIST-LIKE BIOLOGICAL ACTIVITY | ALLERGAN SALES, INC. (US) | 1997-12-24 | — | — | WO | disclosed |
| WO-1997011705-A1 | PHOSPHORYLAMIDES, THEIR PREPARATION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-04-03 | — | — | WO | disclosed |
| WO-1997009297-A2 | SYNTHESIS AND USE OF RETINOID COMPOUNDS HAVING NEGATIVE HORMONE AND/OR ANTAGONIST ACTIVITIES | VISION PHARMACEUTICALS L.P. (US) | 1997-03-13 | — | — | WO | disclosed |
| US-5498755-A | IMINE COMPOUNDS FOR SKIN DISORDERS AND ANTIINFLAMMATORY AGENTS | ALLERGAN, INC. | 1996-03-12 | — | — | US | disclosed |
| WO-1996006070-A1 | DISUBSTITUTED ARYL AND HETEROARYL IMINES HAVING RETINOID-LIKE BIOLOGICAL ACTIVITY | ALLERGAN (US) | 1996-02-29 | — | — | WO | disclosed |
| EP-0393936-B1 | 3-substituted-2-oxindole derivatives as antiinflammatory agents | PFIZER (US) | 1995-02-22 | — | — | EP | disclosed |
| US-5300655-A | 2-carboxy-thiophene derivatives | PFIZER INC. (US) | 1994-04-05 | — | — | US | disclosed |
| US-5290802-A | 3-substituted-2-oxindole derivatives | PFIZER INC. (US) | 1994-03-01 | — | — | US | disclosed |
| US-5047554-A | 3-substituted-2-oxindole derivatives | PFIZER INC. (US) | 1991-09-10 | — | — | US | disclosed |
| EP-0393936-A1 | 3-substituted-2-oxindole derivatives as antiinflammatory agents | PFIZER INC. (US) | 1990-10-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240351984-A1 | INDOLINE COMPOUNDS FOR INHIBITING KIF18A | KIF18A, KIF18B, KIF2C | DAO 4364/4885RARB 3756/4885RARG 3382/4885 |
| US-20230147507-A1 | INDOLINE COMPOUNDS FOR INHIBITING KIF18A | KIF18A, KIF18B, KIF2C | DAO 4364/4885RARB 3756/4885RARG 3382/4885 |
| US-12084420-B2 | Indoline compounds for inhibiting KIF18A | KIF18A, KIF18B, KIF2C | DAO 4298/4885RARB 3782/4885RARG 3435/4885 |
| US-12459956-B2 | Heterobicyclic carboxamides and uses thereof | UACA, PHKG2, CCAR2 | DAO 2798/4885RARB 2644/4885RARG 2592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.